Evidence map›Paper›PMID 34825935›Full record

ReviewDer Urologe. Ausg. A2021

[Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases].

Katharina Rebhan, Kilian M Gust

Erratum issuedOpen access · hybridAbstract readReview
In one paragraph

Review in Der Urologe. Ausg. A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Katharina RebhanUniversitätsklinik für Urologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Kilian M GustUniversitätsklinik für Urologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich. kilian.gust@meduniwien.ac.at.
Klinik und Poliklinik für Urologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of muscle invasive bladder cancer can be challenging since treatment is associated with significant side effects and complication rates-especially in patients who often present with relevant comorbidities. In the metastatic stage, the purpose of treatment is palliation, although the oligometastatic stage takes a distinct role. At this stage, treatment of the primary tumor can play a role, if metastasis can be treated locally in addition to systemic treatment, especially the evolving drug treatment landscape could also change long holding paradigms in the near future.

objectivesThis review focuses on the influence of definitive treatment of the primary tumor in patients with oligometastatic urothelial bladder cancer. MATERIALS AND

methodsBased on a literature search, the aim was to summarize data and give an overview on treatment of oligo-metastatic bladder cancer with focus on treatment of the primary tumor. Presented data derived mostly from retrospective studies and meta-analyses.

conclusionLocal treatment of the primary tumor in context of a multimodal therapy of lymph node metastatic or oligometastatic bladder cancer can have a positive influence on survival, quality of life and prevention of local complications in selected patients. The choice of local treatment should follow the same criteria as in non-metastatic bladder cancer.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsCystectomyHumansQuality of LifeRetrospective StudiesChemotherapyLymph nodesRadiationRadical cystectomyUrothelial cancer

Identifiers

PMID34825935
PMCPMC8654709
OpenAlexW3215647420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.